Navigation Links
Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
Date:9/3/2013

ROCKVILLE, Md., Sept. 3, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE-MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  Mr. Riley is scheduled to present at 12:05 p.m. (Eastern Time) on Monday, September 9, 2013 at the Millennium Broadway Hotel in New York City.

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the internet at http://wsw.com/webcast/rrshq23/SYN. After the presentation, a replay will be archived and accessible for 30 days at the same website.

Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with attendees who are registered for the conference. If you are an institutional investor, and would like to attend the Company's presentation, please register for the Rodman & Renshaw conference using the following link www.rodm.com. Once your registration is confirmed, you will be prompted to log into the conference website and may request a one-on-one meeting with the Company.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE-MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
2. Synthetic Biologics to Report Second Quarter 2013 Financial Results
3. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
4. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
5. Synthetic Biologics to Present at OneMedForum New York 2013
6. New England Biolabs supports iGEM synthetic biology competition
7. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
8. Intrexon Organizes Around New Synthetic Biology Markets
9. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
10. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
11. Express Genes by Eurofins MWG Operon Offers 4 Day Delivery of Synthetic Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
Breaking Biology News(10 mins):